Adela Cañete

Universitat de València — Spain

Medicine · Health Sciences

37h-index5.1kcitations390works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(180), Glioma Diagnosis and Treatment(91), Cancer therapeutics and mechanisms(57), Childhood Cancer Survivors' Quality of Life(56), Cancer, Hypoxia, and Metabolism(43)

Publications387 total

Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial
Journal of Clinical Oncology·2025· 1 citedOpen Access
La influencia de la Constitución española de 1812 en la configuración del poder ejecutivo mexicano en la Constitución de 1824
2025Open Access
Supplementary Figure S4 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
2025Open Access
Supplementary Figure S3 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
2025Open Access
Supplementary Data S1 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
2025Open Access
Supplementary Table S1 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
2025Open Access
Supplementary Table S3 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
2025Open Access
Supplementary Figure S1 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
2025Open Access
Supplementary Table S2 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
2025Open Access
Supplementary Data S2 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
2025Open Access
Supplementary Figure S2 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
2025Open Access
Supplementary Table S5 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
2025Open Access
Supplementary Table S4 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
2025Open Access
Incidence and survival among children with neuroblastoma in Spain over 22 years
BMC Cancer·2025· 3 citedOpen Access
Barriers and facilitators associated with long-term follow-up care for childhood, adolescent, and young adult cancer survivors: a systematic review
BMC Health Services Research·2025· 1 citedOpen Access
Lung nodules in pediatric osteosarcoma: calcification as the most reliable radiological indicator to confirm metastasis
Pediatric Radiology·2025
Abstract A017-PR013: Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: An update from the iMATRIX alectinib phase I/II open-label, multi-center study
Cancer Research·2025
Survival trends and cure rates of hematological neoplasms in the Spanish pediatric population
European Journal of Epidemiology·2025
Management of late toxicities and specific follow-up needs of adolescent and young adult cancer survivors: recommendations from scientific societies in Spain
Clinical & Translational Oncology·2025Open Access
Supplementary Table S3 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
page 1 of 20Next →

Frequent Co-authors

Victoria Castel(26), Ruth Ladenstein(12), Rosa Noguera(10), Yania Yáñez(8), Peter F. Ambros(6), Jean Michon(6), Ulrike Pötschger(5), Samuel Navarro(5), Bruno De Bernardi(5), Jaime Font de Mora(5), Andrew D.J. Pearson(4), Roberto Luksch(4), Ellen Ruud(4), Alberto Garaventa(4), Gilles Vassal(4), Dominique Valteau‐Couanet(4), Marta Piqueras(4), Gudrun Schleiermacher(4), Hervé Rubie(4), Mary Gerrard(4)